Inventor · disambiguated record
Rosa Maria Alvarez Escobar
Also filed as: ALVAREZ ESCOBAR ROSA MARIA · ÁLVAREZ ESCOBAR ROSA MARIA · ÁLVAREZ ESCOBAR ROSA MARÍA
5 granted patents·4 pending applications·35 citations·filing 1999–2022
75Inventor score
Files withJANSSEN PHARMACEUTICA NV2PASTOR FERNÁNDEZ JOAQUIN2PASTOR-FERNANDEZ JOAQUIN2CT NAC INVESTIGACIONES ONCOLOGICAS CNIO1FUNDACION DEL SECTOR PUBLLCO ESTATAL CENTRO NAC DE INVESTIGACIONES ONCOLOGICAS CARLOS III1
Top patents by PatentIndex Score
9 records- 0181US9073927B2Inhibitors of PI3 kinasePASTOR FERNÁNDEZ JOAQUIN·Filed 2011·Granted Jul 7, 2015·14 cites·15 claims
- 0270US9284334B2Macrocyclic compounds as protein kinase inhibitorsPASTOR FERNÁNDEZ JOAQUIN·Filed 2012·Granted Mar 15, 2016·3 cites·11 claims
- 0359US6583141B14,5-dihydro-isoxazole derivatives and their pharmaceutical useJANSSEN PHARMACEUTICA NV·Filed 1999·Granted Jun 24, 2003·18 cites·15 claims
- 0447US2025042918A1CompoundsFUNDACION DEL SECTOR PUBLLCO ESTATAL CENTRO NAC DE INVESTIGACIONES ONCOLOGICAS CARLOS III·Filed 2022·Application pending·0 cites
- 0546US7414048B24,5-dihydro-isoxazole derivatives and their pharmaceutical useJANSSEN PHARMACEUTICA NV·Filed 2003·Granted Aug 19, 2008·0 cites·12 claims
- 0631US9808466B2Macrocyclic compounds as protein kinase inhibitorsFUNDACIÓN CENTRO NAC DE INVESTIG ONCOLOGICAS CARLOS III·Filed 2016·Granted Nov 7, 2017·0 cites·9 claims
- 0729US2013131057A1New bicyclic compounds as pi3-k and mtor inhibitorsPASTOR FERNANDEZ JOAQUIN·Filed 2011·Application pending·0 cites
- 0826US2013065883A1Triazolo [4, 5- B] Pyridin DerivativesPASTOR FERNANDEZ JOAQUIN·Filed 2011·Application pending·0 cites
- 0920US2013029967A1Fused Imidazo [3,2 - D] Pyrazines as P13 Kinase InhibitorsCT NAC INVESTIGACIONES ONCOLOGICAS CNIO·Filed 2010·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Rosa Maria Alvarez Escobar files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →